|
medpundit |
||
 |
 |
|
Wednesday, June 16, 2004Researchers at Harvard Medical School found patients with either of two mutations--single-letter changes in their DNA--saw their cholesterol decrease by about 20% less than other patients when they took the same cholesterol-lowering drug, Bristol-Myers Squibb's Pravachol. In actuality, the differences in cholesterol levels were very small between the two groups, indicating either that we have a lot more to learn about the genetics of the cholesterol-producing enzyme or that the drug interacts with the enzyme in a way that allows a lot of leeway for structural variations. Probably both. Someday we'll be able to test for genes that determine to which drugs we'll respond best, but that day's not here yet. posted by Sydney on 6/16/2004 07:34:00 AM 0 comments 0 Comments: |
|
